Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|Annals of Oncology|2019Cited by 96
Analyzing breast cancer invasive disease event classification through explainable artificial intelligenceRaffaella Massafra, Vito Lorusso, Daniele La Forgia et al.|Frontiers in Medicine|2023Cited by 31
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Valentina Guarneri, Federico Piacentini et al.|Journal of Clinical Oncology|2023Cited by 25
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Giancarlo Bisagni et al.|JAMA Oncology|2025Cited by 17
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trialMaria Vittoria Dieci, V Guarneri, Giancarlo Bisagni et al.|ESMO Open|2025Cited by 0